{"id":334655,"date":"2020-03-23T01:00:00","date_gmt":"2020-03-23T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/une-survie-sans-progression-plus-longue-grace-a-un-traitement-combine\/"},"modified":"2020-03-23T01:00:00","modified_gmt":"2020-03-23T00:00:00","slug":"une-survie-sans-progression-plus-longue-grace-a-un-traitement-combine","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/une-survie-sans-progression-plus-longue-grace-a-un-traitement-combine\/","title":{"rendered":"Une survie sans progression plus longue gr\u00e2ce \u00e0 un traitement combin\u00e9"},"content":{"rendered":"<p><strong>Les r\u00e9sultats des premi\u00e8res \u00e9tudes indiquent que l&#8217;ajout d&#8217;une immunoth\u00e9rapie \u00e0 la chimioth\u00e9rapie conventionnelle pourrait am\u00e9liorer la survie sans progression chez les patients atteints d&#8217;un cancer avanc\u00e9 de la vessie. Un changement de paradigme est-il en train de se produire ?<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>La plus grande \u00e9tude men\u00e9e \u00e0 ce jour sur le carcinome avanc\u00e9 de la vessie, portant sur 1213 patients, a montr\u00e9 que l&#8217;association d&#8217;une chimioth\u00e9rapie et d&#8217;une immunoth\u00e9rapie (atezolizumab) permettait une survie sans progression plus longue que la chimioth\u00e9rapie seule (8,2 mois contre 6,3 mois). En outre, les patients du groupe combin\u00e9 pr\u00e9sentaient un risque de progression inf\u00e9rieur de 18%. En revanche, ce r\u00e9gime th\u00e9rapeutique n&#8217;a pas (encore) marqu\u00e9 de points en termes de survie globale. Dans une \u00e9valuation interm\u00e9diaire, la dur\u00e9e moyenne de survie globale \u00e9tait de 16,0 mois pour l&#8217;association et de 13,4 mois pour la chimioth\u00e9rapie seule (HR : 0,82 ; intervalle de confiance \u00e0 95% [KI]: 0,70-0,96). Une tendance en faveur des traitements combin\u00e9s se dessine. Celle-ci n&#8217;est toutefois pas encore statistiquement significative. Cependant, pour la premi\u00e8re fois, l&#8217;\u00e9tude a inclus \u00e0 la fois des patients sensibles au platine et des patients non adapt\u00e9s au platine. Le traitement \u00e0 base de cisplatine, utilis\u00e9 depuis des ann\u00e9es, est associ\u00e9 \u00e0 des toxicit\u00e9s importantes. De plus, tous les patients ne sont pas \u00e9ligibles \u00e0 ce type de traitement. Personnes concern\u00e9es avec une clairance de la cr\u00e9atinine &lt;60&nbsp;ml\/min, une perte auditive \u22652. Une neuropathie \u22652. Les patients atteints de cancer du poumon du 2e degr\u00e9, d&#8217;insuffisance cardiaque de classe III NYHA ou d&#8217;un statut ECOG \u22652 ne sont pas \u00e9ligibles pour un traitement au cisplatine. Cela concerne environ la moiti\u00e9 de tous les patients atteints de cancer de la vessie. En cons\u00e9quence, une gestion du traitement qui am\u00e9liore la chimioth\u00e9rapie est souhaitable.<\/p>\n<p><em>Source : European Society for Medical Oncology (ESMO) 2019<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>InFo ONKOLOGIE &amp; H\u00c4MATOLOGIE 2019 ; 7(6) : 37 (publi\u00e9 le 10.12.19, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les r\u00e9sultats des premi\u00e8res \u00e9tudes indiquent que l&#8217;ajout d&#8217;une immunoth\u00e9rapie \u00e0 la chimioth\u00e9rapie conventionnelle pourrait am\u00e9liorer la survie sans progression chez les patients atteints d&#8217;un cancer avanc\u00e9 de la vessie.&hellip;<\/p>\n","protected":false},"author":7,"featured_media":93682,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Carcinome avanc\u00e9 de la vessie","footnotes":""},"category":[11527,11389,11535,11549,11514],"tags":[18813,13586,25977],"powerkit_post_featured":[],"class_list":["post-334655","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-oncologie","category-rapports-de-congres","category-rx-fr","category-urologie-fr","tag-carcinome-de-la-vessie","tag-immunotherapie-fr","tag-therapie-combinee","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-18 08:37:57","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":334664,"slug":"prolungamento-della-sopravvivenza-libera-da-progressione-grazie-alla-terapia-combinata","post_title":"Prolungamento della sopravvivenza libera da progressione grazie alla terapia combinata","href":"https:\/\/medizinonline.com\/it\/prolungamento-della-sopravvivenza-libera-da-progressione-grazie-alla-terapia-combinata\/"},"pt_PT":{"locale":"pt_PT","id":334670,"slug":"sobrevivencia-prolongada-sem-progressao-atraves-de-terapia-combinada","post_title":"Sobreviv\u00eancia prolongada sem progress\u00e3o atrav\u00e9s de terapia combinada","href":"https:\/\/medizinonline.com\/pt-pt\/sobrevivencia-prolongada-sem-progressao-atraves-de-terapia-combinada\/"},"es_ES":{"locale":"es_ES","id":334626,"slug":"prolongacion-de-la-supervivencia-libre-de-progresion-mediante-terapia-combinada","post_title":"Prolongaci\u00f3n de la supervivencia libre de progresi\u00f3n mediante terapia combinada","href":"https:\/\/medizinonline.com\/es\/prolongacion-de-la-supervivencia-libre-de-progresion-mediante-terapia-combinada\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/334655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=334655"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/334655\/revisions"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=334655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=334655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=334655"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=334655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}